Darovasertib (LXS-196)
Modify Date: 2024-01-09 17:47:39
Darovasertib (LXS-196) structure
|
Common Name | Darovasertib (LXS-196) | ||
|---|---|---|---|---|
| CAS Number | 1874276-76-2 | Molecular Weight | 472.466 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 592.7±50.0 °C at 760 mmHg | |
| Molecular Formula | C22H23F3N8O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 312.3±30.1 °C | |
Use of Darovasertib (LXS-196)LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma. |
| Name | NVP-LXS196 |
|---|---|
| Synonym | More Synonyms |
| Description | LXS196 is a potent and orally active protein kinase C (PKC) inhibitor under Phase I clinical trials for the treatment of uveal melanoma. |
|---|---|
| Related Catalog | |
| Target |
PKC |
| In Vitro | Upon oral administration, protein kinase C inhibitor LXS196 binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival[1]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 592.7±50.0 °C at 760 mmHg |
| Molecular Formula | C22H23F3N8O |
| Molecular Weight | 472.466 |
| Flash Point | 312.3±30.1 °C |
| Exact Mass | 472.194702 |
| LogP | 3.70 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.622 |
| Storage condition | 2-8℃ |
| 2-Pyrazinecarboxamide, 3-amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]- |
| 3-Amino-N-[3-(4-amino-4-methyl-1-piperidinyl)-2-pyridinyl]-6-[3-(trifluoromethyl)-2-pyridinyl]-2-pyrazinecarboxamide |
| NVP-LXS196 |
| LXS196 |